Table 2.
Univariate analysis for variables that predict persistent control regarding virological p and immunological progression
| Variable | Years to viral failure a | p value | Years to CD4 failure a | p value |
|---|---|---|---|---|
| Age | ||||
| ≤38 | 18 (13 to 23) | 0.007 | 9.5 (1.9 to 17) | 0.13 |
| >38 | 11 (7 to 15) | 5.5 (1.8 to 9.2) | ||
| Sex | ||||
| Male | 12 (7.7 to 16.3) | 0.56 | 7.5 (0 to 15.7) | 0.76 |
| Female | 13 (8.6 to 17.4) | 4 (0.7 to 7.3) | ||
| Risk for HIV acquisition | ||||
| Parenteral | 16 (12.7 to 19.3) | 0.037 | 5.5 (2.8 to 8.2) | 0.96 |
| MSM | 8 (6.9 to 9.1) | 4 (0 to 8.6) | ||
| HET | 12 (7.6 to 16.4) | 9.5 (0.8 to 18.2) | ||
| HCV | ||||
| Negative serology | 8 (5.2 to 10.8) | 0.007 | 7.5 (1.5 to 13.5) | 0.77 |
| Positive serology | 15 (11 to 18.9) | 5.5 (2.1 to 8.9) | ||
| HCV cure | ||||
| Cured | 16 (7.7 to 24.3) | 0.8 | 4 (0.9 to 7) | 0.06 |
| Not cured | 14 (10.8 to 17.2) | 6 (2.1 to 14) | ||
| Nadir CD4+ T cells | ||||
| <414 | 12 (9.3 to 14.7) | 0.12 | N/A | N/A |
| >414 | 14 (8.2 to 19.8) | |||
| Baseline CD4+ T cells | ||||
| <699 | 10 (6.7 to 13.4) | 0.035 | N/A | N/A |
| >700 | 16 (11.7 to 20.3) | |||
| Viral load blips 1st year | ||||
| No | 16 (11.4 to 20.6) | 0.004 | 7.5 (0.9 to 14.1) | 0.1 |
| Yes | 8 (4.2 to 11.8) | 3 (0 to 6.2) | ||
A univariate analysis using Kaplan–Meier estimates and log‐rank tests was performed. HCV, Hepatitis C Virus evaluated at baseline; HET, Heterosexual; MSM, Men who have sex with men.
a
Estimated median (95% confidence interval).